{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:35:24Z","timestamp":1793115324446,"version":"4.5.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Risk stratification to predict treatment failure in chronic-phase chronic myeloid leukemia (CP-CML) remains an important challenge in the tyrosine kinase inhibitor (TKI) era. We conducted a pooled analysis of 710 patients with newly diagnosed CP-CML enrolled in the prospective Japan Adult Leukemia Study Group CML212 and New TARGET studies, \u223c80% of whom received second-generation TKIs (2G-TKIs) as first-line therapy, to identify predictors of failure-free survival (FFS). In this study, we incorporated the European LeukemiaNet 2025\u2013defined \u201cwarning\u201d category as an initial adverse state in the definition of FFS events and evaluated transitions to \u201cunfavorable.\u201d Within this framework, the EUTOS long-term survival (ELTS) score consistently stratified FFS whether treatment failure included both \u201cwarning\u201d and \u201cunfavorable\u201d events or was restricted to \u201cunfavorable.\u201d Among patients treated with 2G-TKIs, ELTS demonstrated superior time-dependent discrimination compared with Sokal and remained the baseline predictor of initial treatment failure. Importantly, once \u201cwarning\u201d occurred, baseline ELTS no longer predicted deterioration. Instead, the attainment of \u201cwarning\u201d within 6 months after TKI initiation independently predicted transition from \u201cwarning\u201d to \u201cunfavorable\u201d (hazard ratio, 7.31; 95% confidence interval, 2.94-18.2; P&amp;lt; .001). These findings distinguish baseline risk from postmilestone disease evolution and support a 2-stage risk framework integrating baseline ELTS stratification with \u201cwarning\u201d timing to guide dynamic risk-adapted management in CP-CML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026021073","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T21:05:50Z","timestamp":1786741550000},"page":"7139-7151","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["ELTS score and early \u201cwarning\u201d define a 2-stage risk framework for failure-free survival in chronic-phase CML"],"prefix":"10.1182","volume":"10","author":[{"given":"Fumisato","family":"Takagi","sequence":"first","affiliation":[{"name":"1Division of Hematology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3922-7432","authenticated-orcid":false,"given":"Takaaki","family":"Ono","sequence":"additional","affiliation":[{"name":"2Department of Transfusion and Cell Therapy, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-0739","authenticated-orcid":false,"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[{"name":"4Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1175-226X","authenticated-orcid":false,"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[{"name":"5Department of Hematology, International University of Health and Welfare, Narita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-1988","authenticated-orcid":false,"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Rheumatology, National Hospital Organization Saitama Hospital, Wako City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumichi","family":"Fujimaki","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Fujisawa City Hospital, Fujisawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Kakihana","sequence":"additional","affiliation":[{"name":"8Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Ogasawara","sequence":"additional","affiliation":[{"name":"9Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Okada","sequence":"additional","affiliation":[{"name":"10First Department of Internal Medicine, Kansai Medical University Medical Center, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuzo","family":"Tauchi","sequence":"additional","affiliation":[{"name":"11Shin-Yurigaoka General Hospital, Kawasaki City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[{"name":"12Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan"},{"name":"13Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5974-7614","authenticated-orcid":false,"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"14Department of Hematology and Oncology, Faculty of Medicine, Shimane University, Izumo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8588-8955","authenticated-orcid":false,"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"15Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0112-6564","authenticated-orcid":false,"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[{"name":"16Kanazawa University, Kanazawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"18Shubun University, Ichinomiya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-1928","authenticated-orcid":false,"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[{"name":"19Department of Hematology, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2028-0209","authenticated-orcid":false,"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-7865","authenticated-orcid":false,"given":"Yukio","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"21International University of Health and Welfare, Mita Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8079-1759","authenticated-orcid":false,"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"22Department of Medical Technology, Faculty of Health Science, Kumamoto Health Science University, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9429-3451","authenticated-orcid":false,"given":"Masahiro","family":"Kizaki","sequence":"additional","affiliation":[{"name":"23Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-9498","authenticated-orcid":false,"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"24Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"25Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2818-4270","authenticated-orcid":false,"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[{"name":"26Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"issue":"10","key":"2026102711123653400_bib1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2026102711123653400_bib2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"20","key":"2026102711123653400_bib3","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026102711123653400_bib4","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"2026102711123653400_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"2026102711123653400_bib6","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026102711123653400_bib7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/ejh.14328","article-title":"Loss in overall and quality-adjusted life expectancy for patients with chronic-phase chronic myeloid leukemia","volume":"114","author":"Chen","year":"2025","journal-title":"Eur J Haematol"},{"issue":"1","key":"2026102711123653400_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2026102711123653400_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12185-024-03865-2","article-title":"JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN)","volume":"121","author":"Takahashi","year":"2025","journal-title":"Int J Hematol"},{"issue":"8","key":"2026102711123653400_bib10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"issue":"4","key":"2026102711123653400_bib11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"1","key":"2026102711123653400_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"2026102711123653400_bib13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41375-021-01387-y","article-title":"Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"2026102711123653400_bib14","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/s41375-021-01292-4","article-title":"EUTOS long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study","volume":"35","author":"Breccia","year":"2021","journal-title":"Leukemia"},{"issue":"23","key":"2026102711123653400_bib15","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1002\/cam4.3516","article-title":"The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort","volume":"9","author":"Sato","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"2026102711123653400_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12185-024-03758-4","article-title":"Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group","volume":"120","author":"Iriyama","year":"2024","journal-title":"Int J Hematol"},{"issue":"22","key":"2026102711123653400_bib17","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2026102711123653400_bib18","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","article-title":"High-risk additional chromosomal abnormalities at low blast counts herald death by CML","volume":"34","author":"Hehlmann","year":"2020","journal-title":"Leukemia"},{"key":"2026102711123653400_bib19","doi-asserted-by":"crossref","first-page":"107349","DOI":"10.1016\/j.leukres.2023.107349","article-title":"The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure","volume":"132","author":"Ratajczak","year":"2023","journal-title":"Leuk Res"},{"issue":"11","key":"2026102711123653400_bib20","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.3324\/haematol.2022.282447","article-title":"High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population","volume":"108","author":"Kockerols","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"2026102711123653400_bib21","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/bloodadvances.2020003570","article-title":"Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression","volume":"5","author":"Clark","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2026102711123653400_bib22","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41375-022-01527-y","article-title":"A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"2026102711123653400_bib23","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/s41375-023-01875-3","article-title":"Validation of the imatinib-therapy failure model","volume":"37","author":"Zhang","year":"2023","journal-title":"Leukemia"},{"issue":"14","key":"2026102711123653400_bib24","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1080\/10428194.2023.2255804","article-title":"Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice","volume":"64","author":"Ielo","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2026102711123653400_bib25","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"18","key":"2026102711123653400_bib26","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.2024024761","article-title":"A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy","volume":"144","author":"Zhang","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2026102711123653400_bib27","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/s41375-025-02703-6","article-title":"Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools","volume":"39","author":"Moinard","year":"2025","journal-title":"Leukemia"},{"issue":"20","key":"2026102711123653400_bib28","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1182\/bloodadvances.2024012655","article-title":"Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study","volume":"8","author":"Matsumura","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2026102711123653400_bib29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12185-019-02613-1","article-title":"Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system","volume":"109","author":"Kizaki","year":"2019","journal-title":"Int J Hematol"},{"issue":"35","key":"2026102711123653400_bib30","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026102711123653400_bib31","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2026102711123653400_bib33","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"2026102711123653400_bib34","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/s41375-025-02606-6","article-title":"Prognostic scoring systems in chronic myeloid leukaemia","volume":"39","author":"Lauseker","year":"2025","journal-title":"Leukemia"},{"issue":"10","key":"2026102711123653400_bib35","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-022-00742-1","article-title":"Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia","volume":"12","author":"Bidikian","year":"2022","journal-title":"Blood Cancer J"},{"issue":"23","key":"2026102711123653400_bib36","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1182\/blood.2025030259","article-title":"Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations","volume":"146","author":"Shanmuganathan","year":"2025","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/7139\/2595810\/blooda_adv-2026-021073-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/7139\/2595810\/blooda_adv-2026-021073-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:12:46Z","timestamp":1793113966000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/20\/7139\/570167\/ELTS-score-and-early-warning-define-a-2-stage-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":35,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026021073","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,27]]},"published":{"date-parts":[[2026,10,19]]}}}